摘要
目的 探讨组织相容性抗原 (HLA) 肽四聚体流式细胞技术检测乙型肝炎病毒特异性CD8+ T细胞的临床应用价值。方法 采用HLA A2分子胞外段与乙型肝炎病毒 (HBV)核心表位肽core 18 2 7结合的HLA 肽四聚体 (Tetramer) ,设计流式细胞技术检测乙肝患者外周血中针对该肽段的特异性CD8+ T细胞数量 ,以占总计数CD8+ 细胞数的百分比表示。结果 11例HLA A2 + 的急性乙肝患者外周血特异性CD8+ T细胞为 0 0 2 %～ 2 0 4 % ,中位数为 0 2 0 % ,16例HLA A2 + 的慢乙肝患者为<0 0 1%～ 0 6 5 % ,中位数为 0 0 5 % ,二组之间差有显著性 (P <0 0 1)。 15例HLA A2 + 正常对照组、13例HLA A2 -急性乙肝对照组和 19例HLA A2 -慢性乙肝对照组的特异性的CD8+ T细胞均不超过0 0 2 %。结论 HLA 肽四聚体流式细胞技术能在体外直接检测HBV特异性的CD8+ T细胞数量 ,其水平一定程度上反映了特异性CTL应答状况 ,且与乙肝的不同临床转归有关。
Objective To evaluate the clinical application of HLA-peptides tetramer staining flow cytometry for determining HBV specific CD8+ cells.Methods HBV specific CD8+ cells in whole blood samples of chronic hepatitis B patients were stained with tetramer complex of HLA-A2 and HBV core 18-27 peptide and counted by flow cytometry. Results The medians of percentages of HBV specific CD8+ cells of total CD8+ cells were 0.20%(0.02%～2.04%) in 11 acute hepatitis B patients and 0.05%(<0.01%～0.65%) in 16 chronic hepatitis B patients respectively. There was statistical difference between the two groups(P<0.01). In three control groups including 15 HLA-A2+ normal people, 13 HLA-A2- acute hepatitis B patients and 19 HLA-A2-chronic hepatitis B patients, none of percentages of HBV specific CD8+ cells exceeded 0.02%. Conclusion HLA-peptides tetramer staining flow cytometry is a direct exvivo method to detect the lever of circulating HBV specific CD8+ cells which reflects the response of CTL and relates to clinical consequence in hepatitis B patients.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2004年第4期221-223,共3页
Chinese Journal of Laboratory Medicine
基金
国家"8 63"计划项目资助 ( 2 0 0 3AA2 0 5 0 15 )
